Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Influence of CILostazol-based Triple Anti-platelet Therapy ON Ischemic Complication After Drug-eluting stenT Implantation
Brief Summary: Objectives :

* To evaluate the influence of concomitant use of cilostazol with aspirin and clopidogrel on the composite cardiovascular adverse outcomes (cardiac death, myocardial infarction, nonhemorrhagic stroke, target lesion revascularization) after drug-eluting stent implantation

Study Design : Prospective, open label, two arm, randomized multicenter trial to test the superiority of cilostazol group compared with the control group. Patients will be randomized according to the use of cilostazol

Patient Enrollment: 960 patients enrolled at 5 centers in Korea

Patient Follow-up : Clinical follow-up will occur at 1, 3 and 6 months. Angiographic follow-up will be recommended to all patient at 6 months after index procedure.

Primary Endpoint

* Composite of adverse cardiovascular/cerebrovascular outcomes (cardiac death, myocardial infarction, nonhemorrhagic stroke, target lesion revascularization) within 6 months

Secondary Endpoint

* All cause of death, stent thrombosis, and each component of primary endpoint at six months
* PRU level measured at discharge after the index procedure and after six months

Safety Endpoint

* Bleeding complications according to TIMI criteria
* The incidence of drug discontinuation
* Heart rate


Options:
A: Arm Label: Aspirin; Type: EXPERIMENTAL; Interventions: Drug: Aspirin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Aspirin | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: aspirin, clopidogrel & sarpogrelate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sarpogrelate, Drug: Aspirin, Drug: Clopidogrel | Arm Label: aspirin, clopidogrel & placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aspirin, Drug: Clopidogrel, Drug: Placebo (for Sarpogrelate) | Intervention Type: DRUG; Name: Sarpogrelate; Assigned to Arm(s): aspirin, clopidogrel & sarpogrelate | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): aspirin, clopidogrel & placebo, aspirin, clopidogrel & sarpogrelate | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): aspirin, clopidogrel & placebo, aspirin, clopidogrel & sarpogrelate | Intervention Type: DRUG; Name: Placebo (for Sarpogrelate); Assigned to Arm(s): aspirin, clopidogrel & placebo
C: Arm Label: TAT; Type: ACTIVE_COMPARATOR; Interventions: Drug: cilostazol | Arm Label: DAT; Type: PLACEBO_COMPARATOR; Interventions: Drug: cilostazol | Intervention Type: DRUG; Name: cilostazol; Assigned to Arm(s): DAT, TAT
D: Arm Label: Active Clonidine and Active ASA; Type: EXPERIMENTAL; Interventions: Drug: Active Clonidine, Drug: Active ASA | Arm Label: Active Clonidine and Placebo ASA; Type: EXPERIMENTAL; Interventions: Drug: Active Clonidine, Drug: Placebo ASA | Arm Label: Placebo Clonidine and Active ASA; Type: EXPERIMENTAL; Interventions: Drug: Placebo Clonidine, Drug: Active ASA | Arm Label: Placebo Clonidine and Placebo ASA; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Clonidine, Drug: Placebo ASA | Intervention Type: DRUG; Name: Active Clonidine; Assigned to Arm(s): Active Clonidine and Active ASA, Active Clonidine and Placebo ASA | Intervention Type: DRUG; Name: Placebo Clonidine; Assigned to Arm(s): Placebo Clonidine and Active ASA, Placebo Clonidine and Placebo ASA | Intervention Type: DRUG; Name: Active ASA; Assigned to Arm(s): Active Clonidine and Active ASA, Placebo Clonidine and Active ASA | Intervention Type: DRUG; Name: Placebo ASA; Assigned to Arm(s): Active Clonidine and Placebo ASA, Placebo Clonidine and Placebo ASA

Answer: C